PagnatoKarp Partners’s Intellia Therapeutics NTLA Stock Holding History

PagnatoKarp Partners’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-12,992	Closed	-$159K	–	97
2020 Q1	$159K	Buy	+12,992	New	+$175K	0.04%	162

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AVAI

Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Chevy Chase Trust Bethesda, Maryland $38.8B AUM 41.35% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

PagnatoKarp Partners's NTLA Position: Q2 2020 in Review

PagnatoKarp Partners sold out of Intellia Therapeutics (NTLA) in Q2 2020, closing a stake of 12,992 shares — an estimated $159K sold.

PagnatoKarp Partners first reported a position in NTLA in Q1 2020 and held it in 1 quarter. The position peaked at $159K in Q1 2020. 164 funds tracked by Wall St. Rank hold NTLA as of Q2 2020.

PagnatoKarp Partners reported no remaining Intellia Therapeutics position as of Q2 2020 after selling out during the quarter.
PagnatoKarp Partners sold 12,992 Intellia Therapeutics shares in Q2 2020, an estimated $159K.
PagnatoKarp Partners first reported a position in Intellia Therapeutics in Q1 2020 and held it in 1 quarter.
PagnatoKarp Partners's Intellia Therapeutics position peaked at $159K in Q1 2020.
164 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2020.

Based on PagnatoKarp Partners's 13F filing for Q2 2020.